Dear Mayo Clinic: How is thyroid cancer treated? Does it always require taking out the thyroid? When is iodine treatment used, and how does that work?
15
0
More imaging after thyroid cancer treatment identifies recurrence, but it does not always improve survival, a new study suggests.
0
0
Women of reproductive age who have thyroid cancer should be cautious about receiving radioactive iodine treatment, which affects their remaining egg supply - their ovarian reserve - and may affect their fertility, new research ...
1
0
In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center ...
9
0
For the first time, researchers have found that exposure to radioactive iodine is associated with more aggressive forms of thyroid cancer, according to a careful study of nearly 12,000 people in Belarus who were exposed when ...
0
0
(Medical Xpress)—The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to a new study from researchers in the Abramson Cancer Center at the University ...
0
0
Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists ...
0
0
Scientists have long sought to determine whether heredity is one of the factors responsible for increased risk of thyroid cancer, but their results have been inconclusive... until now.
0
0
(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.
0
0
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher ...
0
0
Subscribe to rss feed
